Navigation Links
Barrow scientists solve 200-year-old scientific debate involving visual illusions
Date:11/20/2008

Neuroscientists at Barrow Neurological Institute at St. Joseph's Hospital and Medical Center have discovered a direct link between eye motions and the perception of illusory motion that solves a 200-year-old debate.

Stephen Macknik, PhD, director of the Laboratory of Behavioral Neurophysiology; Susana Martinez-Conde, PhD, director of the Laboratory of Visual Neuroscience; Xoana G. Troncoso, PhD; and Jorge Otero-Millan; conducted a study based on the Enigma painting, a visual illusion in which rotational motion is seen within a stationary image. The artwork has been at the center of a debate over whether the brain or the eye is behind the perception of illusory motion.

Dr. Martinez-Conde's laboratory recently discovered that microsaccades, a small, unconscious eye movement that occurs when humans fixate their eyes, are critical to normal vision. The team of scientists conducted the Enigma study to see if microsaccades are also behind the perception of this illusion. Based on their study, the hypothesis suggesting the illusion originates solely in the brain was ruled out.

Participants in the study observed the Enigma illusion while their eye movements were simultaneously recorded with high precision cameras. Microsaccade rates increased before the illusionary motion sped up and decreased before the motion slowed, revealing a direct link between the eye movements and the illusion.

"We have discovered that this illusion originates with eye movements and not solely the brain as previously thought," says Dr. Martinez-Conde. "The findings from the study could help design future prosthetics for patients with brain damage or brain lesions that affect the perception of motion."


'/>"/>

Contact: Carmelle Malkovich
602-406-3319
St. Joseph's Hospital and Medical Center
Source:Eurekalert

Page: 1

Related biology news :

1. Scientists find facial scars increase attractiveness
2. Chicks to give scientists clearer picture of fetal development
3. NYU biologist Bonneau named among 20 "visionary" scientists under 40 by Discover magazine
4. Scientists announce major progress towards historic Census of Marine Life in 2010
5. Washington University scientists first to sequence genome of cancer patient
6. Scripps research scientists identify compounds for stem-cell production from adult cells
7. 12 outstanding young scientists named as EMBO Young Investigators
8. Scripps Florida scientists awarded $1.5M to fight major water and food parasites
9. European biodiversity and ecosystem scientists merge and gear up for long-term research
10. Scientists unveil mechanism for up and down in plants
11. Scientists identify cell changes leading to impaired artificial kidney function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2016. ... compared to $6.9 million in the same quarter last year. ... million compared to $2.6 million in the fourth quarter of ... $0.5 million, or $0.02 per diluted share, which compares to ...
(Date:2/7/2017)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce that the latest release of ... and award winning eClinical solution, is now available for ... a proven Software-as-a-Service (SaaS) clinical research technology platform that ... delivers an entire suite of eClinical tools to support ...
(Date:2/3/2017)... Biomedical Research Institute announced that its Board of Trustees has ... Institute,s new President and CEO. Dr. Schlesinger will take the ... currently the Chair of the Department of Microbial Infection and ... at Ohio State University. "We are delighted to ... Texas Biomed," said Dr. James O. Rubin , Board ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... ... February 24, 2017 , ... Delpor, Inc. (Delpor), a biotechnology company focused on ... of Mental Health (NIMH) for the further advancement of the company’s 3-month olanzapine product ... is expected to deliver therapeutic levels of olanzapine for a period of 3 months., ...
(Date:2/24/2017)... 2017 Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... clinical-stage oncology and dermatology biopharmaceutical company, today is ... in its previously announced rights offering of up ... common stock and Series C Convertible Preferred Stock ... As previously announced, the rights ...
(Date:2/24/2017)... , Feb. 24, 2017 Symic Bio, a ... a new category of therapeutics, announced today the completion ... in peripheral artery disease. The trial will evaluate the ... therapeutic, in the reduction of restenosis following angioplasty. ... development milestone for SB-030," said Nathan Bachtell , ...
(Date:2/24/2017)... -- China Cord Blood Corporation (NYSE: CO ... cord blood collection, laboratory testing, hematopoietic stem cell processing ... financial results for the third quarter and first nine ... Third Quarter of Fiscal 2017 Highlights ... 2017 increased by 18.6% to RMB200.9 million ($28.9 million). ...
Breaking Biology Technology: